Cross-species-specific PSMAxCD3 bispecific single chain antibody

US12281172B2 · kind B2 · utility

Assignee

• AMGEN RESEARCH (MUNICH) GMBH · DE

Inventors

• Peter Kufer · Munich, DE
• Tobias Raum · Munich, DE
• Roman Kischel · Munich, DE
• Ralf Lutterbüse · Munich, DE
• Patrick Hoffmann · Munich, DE
• Doris Rau · Munich, DE
• Susanne Mangold · Munich, DE
• Matthias Klinger · Gilching, DE
• Evelyne Schaller · Munich, DE
• Susanne Hausmann · Dachau, DE
• Petra Fluhr · Munich, DE
• Carola Steiger · Munich, DE

Key dates

• Filing date: Apr 2, 2021
• Grant date: Apr 22, 2025
• Expiry date: Aug 12, 2043

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/34
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to a bispecific single chain antibody molecule comprising a first binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3 epsilon chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2, 4, 6, and 8, and a second binding domain capable of binding to prostate-specific membrane antigen (PSMA). The invention also provides nucleic acids encoding said bispecific single chain antibody molecule as well as vectors and host cells and a process for its production. The invention further relates to pharmaceutical compositions comprising said bispecific single chain antibody molecule and medical uses of said bispecific single chain antibody molecule.